Turn ASCO data into business-critical insights. 30 high-prescribing hem/oncs analyze 10 Prostate Cancer abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for apalutamide, darolutamide, enzalutamide, HPN424, nivolumab, P-PSMA-101, relugolix, ribociclib,┬árucaparib, talazoparib, TAS3681, and 177Lu-PSMA-617 among others. Get your 60+ slide report.

Prostate Cancer Report ASCO 2021

American Society of Clinical Oncology

Virtual Meeting
Jun 4 to Jun 8

Share: